Hematologic Malignancies Market By Type (Lymphoma, Leukemia, Multiple Myeloma), By Therapy (Radiotherapy, Chemotherapy, Immunotherapy), By End-Users (Hospitals, Homecare, Specialty Clinics, and Others) and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI502322 | Publish Date: May 2023 | No. of Pages: 170

Hematologic Malignancies Market Companies

  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • GlaxoSmithKline PLC.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Inc.
  • Celgene Corporation
  • F. Hoffman-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited

Recent News:

  • The U.S. FDA approves Johnson & Johnson's novel blood cancer treatment in October 2022. Adults with multiple myeloma can now be treated with the recently approved treatment teclistamab, also known as "Tecvayli." The recently created "Tecvayli" is a bispecific antibody designed to reroute the immune system so that it can identify and eliminate cancer cells. The recently approved medication "Tecvayli" is the first in its class for the treatment of multiple myeloma.